Cargando…

Non-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report

BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been adopted as the standard of care for non-small cell lung cancer (NSCLC) patients harboring EGFR sensitizing mutations. Besides the two common mutations exon 19 deletion and L858R, which together comprise a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yao, Shen, Ji-Qiao, Shao, Lin, Chen, Yan, Lei, Lei, Wang, Jia-Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462190/ https://www.ncbi.nlm.nih.gov/pubmed/34621884 http://dx.doi.org/10.12998/wjcc.v9.i27.8220

Ejemplares similares

Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low‐dose afatinib: A case report
por: Iida, Yuko, et al.
Publicado: (2019)

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib
por: Longo, Vito, et al.
Publicado: (2021)

Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review
por: Lin, Ruiting, et al.
Publicado: (2021)

LMD-06. A NSCLC patient with leptomeningeal metastasis harboring rare EGFR mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report
por: Wang, Hui, et al.
Publicado: (2021)

An elderly advanced non-small cell lung cancer patient harboring rare epidermal growth factor receptor mutations L861R benefited from afatinib: A case report
por: Qu, Fanjie, et al.
Publicado: (2021)

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review
por: Qin, Bao-Dong, et al.
Publicado: (2018)

Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
por: Long, Xiang, et al.
Publicado: (2020)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
por: Villaruz, L.C., et al.
Publicado: (2023)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
por: Zhao, Yuanyang, et al.
Publicado: (2021)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

EGFR-L861Q突变对TKI类药物敏感性预测分析及病例报道
Publicado: (2015)

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma
por: Abdelmaksoud-Dammak, Rania, et al.
Publicado: (2022)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib
por: Li, Yibin, et al.
Publicado: (2020)

CCM 83.3
Publicado: (1983)

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
por: Song, Yang, et al.
Publicado: (2020)

Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report
por: Liu, Jing, et al.
Publicado: (2019)

L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
por: Li, Meihui, et al.
Publicado: (2022)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature
por: Li, Lin
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience
por: Gürsoy, Pınar, et al.
Publicado: (2022)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

861. Health Disparities in HIV and Pregnancy
por: Abbas, Anum, et al.
Publicado: (2018)

Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation
por: Kawase, Akikazu, et al.
Publicado: (2022)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
por: Shen, Gang, et al.
Publicado: (2021)

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review
por: Li, Linlin, et al.
Publicado: (2023)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
por: Pan, Hai, et al.
Publicado: (2023)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
por: Li, Guangrui, et al.
Publicado: (2023)

A L833V/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review
por: Yang, Xian, et al.
Publicado: (2022)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

罕见EGFR L833V/H835L复合突变的肺腺癌患者1例及文献回顾
por: MIAO, Yongen, et al.
Publicado: (2023)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Fundus Examination of 23,861 Newborns by Digital Imaging in Ningbo
por: Liu, Delin, et al.
Publicado: (2021)

833. Interaction between Aspergillus fumigatus and non-tuberculous mycobacteria
por: Namie, Hotaka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sl5jlnik9jf07143sce5i5poj4